**Abstract**

**Objective:** For the treatment of the patients with treatment-resistant schizophrenia, clozapine is recommended as the drug of choice, but still causes insufficient responses in 40 to 70 % of the patients having been treated with clozapine. The electroconvulsive therapy (ECT) might be an effective and safe option increasing clinical effects. This study was aimed to explore the ECT ugmenting effects for patients with clozapine-resistant schizophrenia.

**Methods:** By using retrospective chart reviews, nine in-patients with clozapine-resistant schizophrenia who had received ECT at Dongguk University International Hospital were recruited. Clozapine resistance is defined as persistent psychotic symptoms despite of clozapine treatment at least for 12 weeks with blood clozapine levels over 350ng/ml. The bilateral electrode was applied and MECTA spECTrum 5000Q^®^ was used underg eneral anesthesia. We explored the changes of psychopathology with the PANSS through ECT and the correlational factors.

**Results:** In nine patients, the mean reduction of the PANSS total score after ECT was 17.8 (SD = 11.6) which was significant (p = 0.0092). The mean reduction rate was 25.0 % (SD = 13.0) from the baseline using 0--6 rating system. The mean clozapine doses were 388.9 (SD = 153.1) mg before ECT and 286.1 (SD = 97.7) mg after ECT with no significant changes. The mean clozapine blood levels of nine patients were 632.2 (SD = 146.9) and 552.7 (SD = 216.4) ng/mL before and after ECT respectively with no significant changes. Six (67.8 %) patients showed responses with the traditional criteria of 20% reduction used in medication-resistant schizophrenia trials.

**Conclusion:** The result of the retrospective case series report showed that ECT augmentation on clozapine-resistance had additional clinical benefits without any persistent adverse effects. The ECT augmentation can be a favorable strategy for the treatment of clozapine-resistant schizophrenia.
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